- Home
- WAVE vs AIM Comparison
WAVE vs AIM Comparison
Compare WAVE & AIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WAVE
- AIM
- Stock Information
- Founded
- WAVE 2011
- AIM 1966
- Country
- WAVE Israel
- AIM United States
- Employees
- WAVE N/A
- AIM N/A
- Industry
- WAVE Electric Utilities: Central
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WAVE Utilities
- AIM Health Care
- Exchange
- WAVE Nasdaq
- AIM Nasdaq
- Market Cap
- WAVE 13.9M
- AIM 15.9M
- IPO Year
- WAVE 2021
- AIM N/A
- Fundamental
- Price
- WAVE $11.61
- AIM $0.22
- Analyst Decision
- WAVE
- AIM Strong Buy
- Analyst Count
- WAVE 0
- AIM 2
- Target Price
- WAVE N/A
- AIM $3.00
- AVG Volume (30 Days)
- WAVE 108.4K
- AIM 671.5K
- Earning Date
- WAVE 11-21-2024
- AIM 11-15-2024
- Dividend Yield
- WAVE N/A
- AIM N/A
- EPS Growth
- WAVE N/A
- AIM N/A
- EPS
- WAVE N/A
- AIM N/A
- Revenue
- WAVE $279,000.00
- AIM $190,000.00
- Revenue This Year
- WAVE N/A
- AIM N/A
- Revenue Next Year
- WAVE N/A
- AIM $1,086.80
- P/E Ratio
- WAVE N/A
- AIM N/A
- Revenue Growth
- WAVE 933.33
- AIM N/A
- 52 Week Low
- WAVE $1.01
- AIM $0.16
- 52 Week High
- WAVE $12.39
- AIM $0.62
- Technical
- Relative Strength Index (RSI)
- WAVE 66.40
- AIM 46.03
- Support Level
- WAVE $6.01
- AIM $0.16
- Resistance Level
- WAVE $9.99
- AIM $0.27
- Average True Range (ATR)
- WAVE 1.22
- AIM 0.03
- MACD
- WAVE 0.37
- AIM -0.00
- Stochastic Oscillator
- WAVE 93.49
- AIM 59.00
About WAVE Eco Wave Power Global AB (publ)
Eco Wave Power Global AB is a Sweden-based wave energy company engaged in the development of a smart and cost-efficient WEC, technology that converts ocean and sea waves into clean electricity. Its WEC technology employs units of point absorber floating devices, referred to as floaters, which are installed on existing marine structures such as piers, breakwaters, and jetties, or in locations in which such marine structures are required. Geographical presence in Israel, USA and Mexico.
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.